SCHEMBL5444273

SCHEMBL5444273

COc1ccc(OCc2nnc(NC(=O)Nc3cccc(Cl)c3)s2)cc1OC

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPN P05981 1/20 0.76
MAPT P10636 6/20 0.58
MEN1 O00255 5/20 0.58
KMT2A Q03164 5/20 0.58
RAB9A P51151 4/20 0.58
LMNA P02545 3/20 0.58
HTT P42858 3/20 0.58
PAX8 Q06710 1/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
L3MBTL1 Q9Y468 1/20 0.56
NPC1 O15118 3/20 0.55
GAA P10253 1/20 0.55
USP2 O75604 1/20 0.54
CCNC P24863 1/20 0.53
CDK8 P49336 1/20 0.53
PTPRE P23469 3/20 0.53
ALOX5 P09917 2/20 0.52
EPHX2 P34913 2/20 0.52
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5443077 0.90 HPN (0.64) HPNMAPTMEN1KMT2ARAB9A
SCHEMBL5435721 0.87 HPN (0.57) HPNMAPTMEN1KMT2ARAB9A
SCHEMBL2029608 0.87 HPN (1.00) HPNMAPTMEN1KMT2ARAB9A
SCHEMBL5442574 0.86 MAPT (0.58) HPNMAPTMEN1KMT2ARAB9A
SCHEMBL5450985 0.85 KMT2A (0.72) MAPTMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL5439686 0.84 MEN1 (0.60) HPNMAPTMEN1KMT2ARAB9A
SCHEMBL5435490 0.83 LMNA (0.58) HPNMAPTMEN1KMT2ARAB9A
SCHEMBL5447957 0.83 MAPT (0.56) HPNMAPTMEN1KMT2ARAB9A
SCHEMBL5450981 0.82 MAPT (0.59) HPNMAPTMEN1KMT2ARAB9A
SCHEMBL5442863 0.81 MAPT (0.58) HPNMAPTMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191353-A1 Use of thiadiazoleurea derivatives MERCK PATENT GMBH (DE) 2007-08-16 US claimed
US-20070191353-A1 Use of thiadiazoleurea derivatives MERCK PATENT GMBH (DE) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191353-A1 Use of thiadiazoleurea derivatives RAF1, ARAF, JAK1 HPN 4058/4885MAPT 3983/4885MEN1 1756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.